February 1, 2012 9:15 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Jefferies & Company has published a research report on Medivation (NASDAQ: MDVN) after the company reported robust AFFIRM data on all front last night.In the report, Jefferies writes, "Three months ago, MDVN released overall survival data and observed an OS improvement of 4.8 months with MDV3100 (18.4 months vs 13.6 months with placebo; p < 0.0001). The company release additional efficacy data, and reveals a tight correlation between improvement in radiographic PFS and time to PSA progression to OS benefit. A highly significant improvement of 5.4 months and 5.3 months was observed with radiographic PFS and time to PSA progression, respectively. Comparatively, J&J's (JNJ; $65.91, NC) Zytiga in the '301 trial observed only a 2-month improvement in PFS. MDV3100's OS results will hold up to FDA scrutiny given the drug arm was not impacted by post-progression treatments."Jefferies maintains its Buy rating and has raised the price target from $62 to $95 on Medivation, which closed yesterday at $55.41.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.